Canton Strategic Holdings (CNTN) Cash from Financing Activities (2021 - 2026)
Canton Strategic Holdings' (CNTN) quarterly Cash from Financing Activities came in at $87.0 million in Q1 2026, up 42200.79% YoY from N/an in Q1 2025, and down 10.76% on a QoQ basis from $97.4 million in Q4 2025.
Analysis
Canton Strategic Holdings (CNTN) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Canton Strategic Holdings (CNTN) has 6 years of Cash from Financing Activities data on file, last reported at $87.0 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 42200.79% year-over-year to $87.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $193.9 million (up 5579.56% YoY) and the FY2025 annual result came in at $107.2 million, up 2939.54% from the prior year.
- Cash from Financing Activities fell to $87.0 million in Q1 2026, from $97.4 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $97.4 million in Q4 2025 to a low of -$338585.0 in Q3 2022.
- A 5-year average of $13.1 million and a median of $1.6 million in 2024 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities sank 485.1% — and 2026, when it surged 42200.79%.
- Tracing CNTN's Cash from Financing Activities over 5 years: stood at -$193457.0 in 2022, then surged by 5094.25% to $9.7 million in 2023, then slumped by 81.18% to $1.8 million in 2024, then soared by 5257.28% to $97.4 million in 2025, then decreased by 10.76% to $87.0 million in 2026.
- The last three Cash from Financing Activities figures came in at $87.0 million (Q1 2026), $97.4 million (Q4 2025), and $7.2 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Canton Strategic Holdings | 493.37 Mn | 493.37 Mn | - | 4.29 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.29 Mn |
| Mar 31, 2026 | 86.96 Mn |
| Dec 31, 2025 | 97.44 Mn |
| Sep 30, 2025 | 7.22 Mn |
| Jun 30, 2025 | 2.31 Mn |
| Mar 31, 2025 | 205,568.00 |
| Dec 31, 2024 | 1.82 Mn |
| Sep 30, 2024 | -257,730.00 |
| Jun 30, 2024 | 1.65 Mn |
| Mar 31, 2024 | 317,119.00 |
| Dec 31, 2023 | 9.66 Mn |
| Sep 30, 2023 | -306,006.00 |
| Jun 30, 2023 | 1.85 Mn |
| Mar 31, 2023 | 523,364.00 |
| Dec 31, 2022 | -193,457.00 |
| Sep 30, 2022 | -338,585.00 |
| Jun 30, 2022 | -249,643.00 |
| Mar 31, 2022 | 13.85 Mn |
| Dec 31, 2021 | -33,064.00 |
| Sep 30, 2021 | 332,600.00 |